Haemonetics
Haemonetics

Haemonetics

Health Care Equipment & Supplies
WebsiteInvestor RelationsSEC
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

$4.6B

Market Cap • 9/10/2026

1971

(55 years)

Founded

1991

(35 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

5,5

P/S

3,4

P/EBITDA

17

P/OCF

14

P/FCF

15,8

P/E

49,5

BVPS

17,9

EPS

2

Market Cap

Market Cap

4,6B

EV

5,5B

EV/Revenue

4,1

EV/EBITDA

20,5

EV/EBIT

34,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

3,7%

Total Yield

3,7%

Payout

0%

Retained Earnings

311,5M

Profitability

Gross Margin

59%

EBITDA Margin

20%

EBIT Margin

11,9%

Net Margin

7,1%

D&A/EBITDA

15,8%

R&D/Revenue

4,4%

Capex/Revenue

2,7%

Capex/D&A

33,6%

Capex/OCF

11,3%

SBC/OCF

10,3%

% PPE

12,8%

% Goodwill

27,8%

ROE

11,2%

ROIC

6,3%

Growth

CAGR Revenue 5Y

8,4%

CAGR Op. Income 5Y

15,1%

CAGR Net Income 5Y

8,3%

CAGR EPS 5Y

10,3%

CAGR OCF 5Y

28,1%

Leverage

N.D./EBITDA

3,5

Debt/Equity

0%

Current Ratio

3,1

Quick Ratio

1,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium